Genetic testing for risk of causing serious adverse reactions of skin of carbamazepine

A technology of adverse reactions and carbamazepine, which is applied in the field of molecular biology and medicine, can solve the problems such as the unreported correlation of HLA-B*1502 gene

Inactive Publication Date: 2011-06-29
XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the correlation bet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0008] Example The use of detection kits

[0009] Step 1: Extraction of DNA template

[0010] Genomic DNA of oral epithelial cells was extracted by silica gel adsorption.

[0011] Step 2: Real-time quantitative PCR reaction

[0012] Use the fluorescent quantitative PCR kit in the detection kit to carry out the fluorescent quantitative PCR reaction. The reaction system has a total volume of 10 μl, including 2 μl of DNA template with a concentration of 20 ng / μl, 1 μl of 10X fluorescent quantitative PCR reaction buffer, and 0.1 μl of 25 mM dNTP mixture solution, 0.6μl 25mM MgCl 2 solution, 0.025 μl (5 units / μl) Taq DNA polymerase, 0.225 μl each of 20 μM sense primer and antisense primer, 0.25 μl each of 10 μM fluorescent probe with VIC and fluorescent probe with FAM, and 5.325 μl of deionized water.

[0013] The reaction was carried out on a PCR amplification instrument, and the reaction conditions were 50° C. for 2 minutes, 95° C. for 10 minutes, and 60 cycles of 95° C. for 3...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a genetic testing method for risk of causing serious adverse reactions of carbamazepine. The genetic testing method comprises the following steps: collecting oral mucosa cells of a subject, extracting genome DNA (deoxyribonucleic acid) of the oral mucosa cells, testing HLA (human leukocyte antigen)-B*1502 allelotype of the genome DNA and evaluating the risk of causing the serious adverse reactions of the skin of an anti-epileptic medicament-carbamazepine, thereby providing reference basis for clinical individual medication.

Description

technical field [0001] The invention relates to the fields of molecular biology and medicine, and more specifically, the invention relates to a method for controlling the risk of serious skin adverse reactions caused by carbamazepine through genetic testing. Background technique [0002] Epilepsy is a disease and syndrome characterized by intermittent central nervous system dysfunction caused by repeated and sudden excessive discharge of neurons in the brain. Antiepileptic drugs are of particular importance in the treatment of epileptic seizures. Carbamazepine (CBZ) is a commonly used first-line antiepileptic drug in clinical practice for the treatment of oral and maxillofacial trigeminal neuralgia, glossopharyngeal neuralgia and seizures. However, CBZ is prone to produce various toxic and side effects during use, even life-threatening. Skin damage is common among them. About 10% of patients who take it for a long time are prone to rash, eczema, urticaria, dermatomyositis, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/68G01N21/64
Inventor 冯哲民邹祖烨贺宪民
Owner XINBAXIANG SHANGHAI MOLECULAR MEDICAL TECH SHANGHAI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap